Navigation Links
Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years
Date:11/8/2010

REDWOOD CITY, Calif., Nov. 8, 2010 /PRNewswire/ -- Arstasis is pleased to announce that patient enrollment has begun in the RECITAL (A Patient Registry Evaluating Closure Following Access with the Arstasis One Access System) Study.  The non-randomized, prospective, post-approval study is anticipated to enroll up to 500 patients in at least seven U.S. hospitals.  The goal of the study is to observe the clinical safety and effectiveness of the Arstasis One Access System in patients undergoing diagnostic angiography procedures through the femoral artery.

The first patient was enrolled at La Paz Regional Medical Center in Parker, Arizona.  "We've begun performing Arstaotomy procedures routinely in our cath lab because they make femoral artery access safer for our patients, easier for me and my staff, and less expensive for our hospital compared with closure devices or manual compression," said Dr. Frank Kresock, chief of interventional cardiology at La Paz Regional Medical Center, the physician who performed the procedure.

Since 1959, physicians have been using the Modified Seldinger Technique (or "Seldinger Technique" for short) to insert flexible catheters into the femoral artery of patients for the purpose of performing procedures in the patient's arterial-vascular system.  The most prevalent such procedure, angiography, is thought to be performed more than half a million times per month worldwide.  At the end of every such case, each patient is left with a substantial hole in his/her femoral artery (upper inner thigh) which typically takes significant effort and cath lab resources to get to stop bleeding.  With the Arstasis One Access System, however, physicians may create a shallow-angle needle pathway through the wall of the femoral artery.  At the end of the procedure, when the sheath is withdrawn, the shallow-angle pathway collapses from the normal pressure of the patient's femoral artery blood flow from below and approximately 3-4 minutes of mild, non-occlusive finger-pressure from above, resulting in a quickly sealing access site.

"The Arstasis One femoral artery access system marks the beginning of a new approach to heart catheterization," commented Zoltan G. Turi, MD, the Director of the Vascular Center at Cooper University Hospital and Professor of Medicine at Robert Wood Johnson Medical School in Camden, New Jersey, and the national principal investigator of the RECITAL study.  "We hope to show that patients who participate in this study benefit from femoral artery closure that has advantages over regular manual compression", Dr. Turi continued. "We are also interested in this technology because Arstasis facilitated closure, unlike vascular closure devices, does not result in any foreign materials being implanted."

The study will also assess patient satisfaction due to reduction of pain and discomfort as well as early mobility.  In non-U.S. clinical trials the resulting closed access site was typically so secure that patients could get up from their beds and begin walking hours sooner than would be the case with a standard femoral arteriotomy, sometimes as soon as those patients receiving Vessel Closure Devices.

"This procedure over the Angioseal, in my opinion, was 100% better because of the recovery time, less swelling and bruising. This is much better, I'm glad I got the Arstaotomy," said Russell McKenzie, Dr. Kresock's 75-year old patient at La Paz Regional Medical Center who was the first to enroll in the RECITAL study.

Detailed information about the Arstasis One, and the Arstaotomy procedure, is available at www.arstasis.com.

ABOUT ARSTASIS, INC.

Arstasis, Inc., headquartered in Redwood City, California, is a medical device manufacturer dedicated to bringing innovative access devices to cardiologists, interventional radiologists, their staffs, and patients.  The company's first product, the Arstasis One, was cleared for U.S. commercialization by the FDA in 2010.  The device is used in the Arstaotomy™ procedure, a new way to gain access to the femoral artery that improves upon the Seldinger Technique and that some physicians believe results in a more pleasant and efficient cath lab and post-procedure experience for clinician and patient alike.INVESTOR/MEDIA CONTACTAlexander Arrow, CFO(650) 508-1549investorrelations@arstasis.com
'/>"/>

SOURCE Arstasis
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
2. Seven-Year Neck Pain Study Sheds Light on Best Care
3. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
4. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
5. In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Trinity Health Selects Seven Elsevier Clinical Decision Support Solutions for its Multiple Facilities In Seven States
8. US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium
9. BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in Chinas National Insurance Catalog
10. Seven New Biopharmaceutical Research Companies Join PhRMAs Mission to Advance Medical Innovation
11. Bioniche Pharma Acquires Seven New Products From GeneraMedix Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... in the ECG Cables And ECG Leadwires Market owing to ... devices. On the other hand, the Asia-Pacific ... rate during the forecast period. The market players ... plc ( Ireland ), Koninklijke Philips N.V. ( ... ( China ), held major share of the ...
(Date:12/2/2016)... PUNE, India , December 2, 2016 /PRNewswire/ ... research report "In Vitro Diagnostics/IVD Market by Product ... Diagnostics, Hematology), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious ... the global market is valued at USD 60.22 ... grow at a CAGR of 5.5% during the ...
(Date:12/2/2016)... On Thursday, December 1st 2016, ... research, development and innovation in the biopharmaceutical industry at ... in the presence of Sergey Tsyb, Vice Minister of ... , Natalia Sanina, First Vice Chairman of the ... of Roszdravnadzor, National Service of Control in Healthcare, Sergey ...
Breaking Medicine Technology:
(Date:12/2/2016)... Milford, NJ (PRWEB) , ... December 02, 2016 , ... ... Nothing Water has some unique properties including its unmatched natural purity of just 6 ... as clean and crisp. , Nothing Water has been available in several ShopRite and ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 ... the National Family Partnership and the Drug Enforcement Administration as part of the National ... the 10 winning schools who decorated their campuses with this year’s Red Ribbon Week ...
(Date:11/30/2016)... PALMYRA, Wisconsin (PRWEB) , ... November 30, 2016 ... ... inclusion in the 2016 Deloitte Wisconsin 75, an annual ranking and recognition of ... consecutive year on the list, having ranked from 2008-2016. In addition, Standard Process ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... and stylish design wanted by today’s consumers at an affordable price, is now ... says the new watch is “a game changer” when it comes to the ...
Breaking Medicine News(10 mins):